Ripretinib For Treating Gastrointestinal Stromal Tumors
Patent No. EP4013412 (titled "Ripretinib For Treating Gastrointestinal Stromal Tumors") was filed by Deciphera Pharmaceuticals on Aug 12, 2020. The application was issued on Jan 28, 2026.
Patent Summary
Patent Family
Statuses, jurisdictions and citation links are shared on request.
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
EP4013412
- Application Number
- EP20761089A
- Filing Date
- Aug 12, 2020
- Status
- Granted And Under Opposition
- Dec 26, 2025
- Publication Date
- Jan 28, 2026
- External Links
- Slate, Register , Google Patents